Synactix Pharmaceuticals, Inc.
Pharmaceuticals - Tucson, Arizona, United States
Synactix Pharmaceuticals, Inc. Employees
Synactix Pharmaceuticals, Inc. Details
The National Cancer Act was signed into law in 1971 by Richard Nixon. At present, 45 years later, cancer is still a leading cause of death with an annual diagnosis of 14.1 million and 8.2 million deaths worldwide. Synactix Pharmaceuticals, Inc. was established to help decrease the catastrophic burden cancer has placed on global health. Instead of looking at cancer as a whole, Synactix identifies specific malignant pathways in particular cancers that are amenable to therapeutic intervention. Using bioinformatics, pathways that are interdependent are identified and a single-agent is created that can block both pathways at the same therapeutic dose. In oncology, resistance is the major limitation for successful treatment of cancers and Synactix had invented an effective strategy to block multiple, malignant pathways to decrease the frequency of resistant disease. Synactix is revolutionizing precision medicine through the strategic targeting of multiple-disease pathways with a single-agent. This is a breakthrough in precision medicine and will lead to treatments that can safely and effectively treat cancers, while simultaneously lowering its burden on global health.
Synactix Pharmaceuticals, Inc. Technologies
Email Providers
Gmail
Load Balancers
Apache
Fonts
Google Font API
Other
Mobile Friendly